Elie Abed, MD
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1235579202
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 539 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations.
Across 539 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Abbott$868
- AstraZeneca$795
- Novo Nordisk$672
- Bayer$630
- Dexcom, Inc.$570
- plus $5K from 33 others
Across 14 payments — averaging $1274.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$18K
What the payments were for
- Food & beverage$9,631100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 76 | $1,218 |
| Abbott | 53 | $868 |
| AstraZeneca(2 entities) | 26 | $795 |
| Novo Nordisk | 48 | $672 |
| Bayer | 38 | $630 |
| Dexcom, Inc. | 46 | $570 |
| Novartis | 26 | $445 |
| Boehringer Ingelheim | 26 | $424 |
| Esperion Therapeutics, Inc. | 16 | $418 |
| Amgen | 26 | $387 |
| Amneal Pharmaceuticals LLC | 16 | $327 |
| Insulet Corporation | 10 | $326 |
| Xeris Pharmaceuticals, Inc. | 16 | $315 |
| Tandem Diabetes Care, Inc. | 12 | $301 |
| Corcept Therapeutics | 14 | $240 |
| Mannkind Corporation | 14 | $239 |
| Kyowa Kirin, Inc. | 8 | $184 |
| AbbVie | 9 | $150 |
| Johnson & Johnson | 4 | $131 |
| Antares Pharma, Inc. | 8 | $127 |
| Currax Pharmaceuticals LLC | 8 | $123 |
| Recordati_rare_diseases_inc. | 4 | $99 |
| Astellas Pharma US Inc | 4 | $92 |
| BETA Bionics, Inc. | 3 | $70 |
| Ascendis Pharma Endocrinology Inc | 3 | $60 |
| Medtronic | 3 | $52 |
| Intra-sana Laboratories | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Rhythm Pharmaceuticals, Inc. | 1 | $31 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Gilead | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $23 |
| Surmodics, Inc. | 1 | $16 |
| Halozyme Inc | 1 | $14 |
| Merck | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,640 in reported general payments places this provider in the 75th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 551 | $785,291 |
| MounjaroTirzepatide | 462 | $585,144 |
| TrulicityDulaglutide | 228 | $323,692 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 120 | $244,779 |
| FarxigaDapagliflozin Propanediol | 182 | $192,783 |
| Tresiba Flextouch U-200Insulin Degludec | 174 | $191,663 |
| JardianceEmpagliflozin | 166 | $185,412 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $143,962 |
| ProliaDenosumab | 69 | $122,450 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 56 | $83,334 |
| VascepaIcosapent Ethyl | 108 | $70,145 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 67 | $62,023 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $57,559 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $52,813 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $46,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,218 | $916,624713 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $672 | $830,576592 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $424 | $290,181242 claims |
| AstraZenecaFarxiga | $795 | $192,783182 claims |
| AmgenProlia | $387 | $122,45069 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $48 | $34,84229 claims |
| AbbVieSynthroid | $150 | $19,095240 claims |
| MerckJanuvia | $13 | $16,55717 claims |
| Antares Pharma, Inc.Xyosted | $127 | $12,99721 claims |
| BayerKerendia | $630 | $8,22811 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $327 | $6,515764 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Tulsa
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Vishnu Priya PulipatiTulsa$8K
- Maria VargasTulsa$7K
- Christian HansonTulsa$4K
- Miguel Jara PalaciosTulsa$4K
- Deepa PhilipTulsa$4K
- Alekya PolojuTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.